Compare SLAI & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
SOLAI Limited American Depositary Shares (each representing one hundred (100) Class A Ordinary Shares)
Current Price
Current Price
| Metric | SLAI | AYTU |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.1M | 23.4M |
| IPO Year | N/A | N/A |
| Metric | SLAI | AYTU |
|---|---|---|
| Price | $0.89 | $2.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | ★ 98.3K | 94.5K |
| Earning Date | 11-21-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $24,209,000.00 | ★ $63,696,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $47.32 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.87 | $0.95 |
| 52 Week High | $8.07 | $2.82 |
| Indicator | SLAI | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 56.25 |
| Support Level | N/A | $2.05 |
| Resistance Level | N/A | $2.67 |
| Average True Range (ATR) | 0.00 | 0.14 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 50.83 |
SOLAI Ltd is a technology-driven cryptocurrency infrastructure company. It is expanding from its foundation in crypto mining to build a blockchain-based ecosystem spanning AI, stablecoins, and payment infrastructure, and Solana treasury and staking operations supporting use cases across institutional settlement, commerce, consumer payments, and AI-native agent transactions. The group is leveraging its blockchain and data infrastructure expertise, aiming to enhance on-chain efficiency and expand participation across Solana and other blockchain ecosystems.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.